ClinicalTrials.gg
CompletedNCT01104792Updated Jul 26, 2019Results posted

Long-term Study of Cariprazine in Patients With Schizophrenia

A Phase 3 interventional study of Cariprazine in Schizophrenia, sponsored by Forest Laboratories. Completed at 86 sites in 6 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2019-07-26.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
752
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing cariprazine in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. cariprazine · Schizophrenia.

Enrollment
2nd of 23
752 · median 129
Started
2010
with 2 others
Phase 3
8 of 23
1 open now
Registered
6th of 23
by date
Lead sponsor
8 of 23
Forest Laboratories

Among the 23 studies testing cariprazine in Schizophrenia, this one is the 2nd largest by enrollment, is one of 3 that started in 2010, is one of 8 in phase 3, and was the 6th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 23 studies testing cariprazine in Schizophrenia are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cariprazine

cariprazine: first FDA approval 2015 (VRAYLAR), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing cariprazine in Schizophrenia, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with schizophrenia.

03

Conditions studied

  • Schizophrenia

Keywords

  • Schizophrenia
  • Acute schizophrenia
  • Psychotropic drugs
  • Antipsychotic agents
  • Mental disorders
  • Dopamine agents
  • Central nervous system agents
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients and corresponding caregivers who have provided informed consents prior to any study specific procedures.
  • Patients currently meeting the , Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia (paranoid type, disorganized type, catatonic type, or undifferentiated type), as confirmed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (SCID).
  • Patients with normal physical examination, laboratory, vital signs, and (ECG).

Exclusion criteria

Exclusion Criteria:

  • Patients with a diagnosis of schizoaffective disorder, schizophreniform disorder, bipolar I or bipolar II disorder, or psychotic disorders other than schizophrenia.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
752 participants (actual)

Study arms

  • Experimental
    Cariprazine

    Participants received cariprazine 3.0, 4.5, 6.0, or 9.0 mg orally once a day for 48 weeks.

    Drug: Cariprazine

Interventions

  • Cariprazine was supplied in capsules.

    Also known as: RGH-188

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 48 in the PANSS Total Score

    The Positive and Negative Syndrome Scale (PANSS) is a 30-item rating scale that assesses the positive and negative symptoms of individuals with schizophrenia. Responses to the 30 items are based on a structured clinical interview with the patient and on supporting clinical information obtained from family, hospital staff, or other reliable informants. Of the 30 psychiatric parameters measured by the scale, 7 assess positive symptoms (eg, delusions, grandiosity); 7 assess negative symptoms (eg, blunted affect, emotional withdrawal); and 16 assess general psychopathology (eg, poor attention, active social avoidance). Each item is scored on a 7-point scale (1 = absent, 2 = minimal, 3 = mild, 4 = moderate, 5 = moderately severe, 6 = severe, and 7 = extreme). The PANSS total score can range from 30 to 210. A higher score indicates worse symptoms. A negative change score indicates improvement.

    Time frame: Baseline to Week 48

Secondary outcomes

  1. Change From Baseline to Week 48 in the CGI-S Score

    The Clinical Global Impressions-Severity (CGI-S) scale is a 7-point scale that measures the overall severity of the illness compared with the severity of illness in other patients the Investigator has observed. The Investigator assesses the severity of the patient's illness as one of the following: 1 = Normal, not at all ill; 2 = Borderline ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill patients. The CGI-S score can range from 1 to 7. A higher score indicates more severe illness. A negative change score indicates improvement.

    Time frame: Baseline to Week 48

07

Results

Posted Jul 26, 2019

Participant flow

Participant flow — Overall Study
MilestoneCariprazine
Started752
Completed226
Not completed526
Withdrew: Adverse event77
Withdrew: Insufficient therapeutic response22
Withdrew: Protocol violation45
Withdrew: Withdrawal of consent179
Withdrew: Lost to follow-up43
Withdrew: Reasons not specified27
Withdrew: Did not meet eligibility criteria133

Outcome measures

PrimaryChange From Baseline to Week 48 in the PANSS Total Score

The Positive and Negative Syndrome Scale (PANSS) is a 30-item rating scale that assesses the positive and negative symptoms of individuals with schizophrenia. Responses to the 30 items are based on a structured clinical interview with the patient and on supporting clinical information obtained from family, hospital staff, or other reliable informants. Of the 30 psychiatric parameters measured by the scale, 7 assess positive symptoms (eg, delusions, grandiosity); 7 assess negative symptoms (eg, blunted affect, emotional withdrawal); and 16 assess general psychopathology (eg, poor attention, active social avoidance). Each item is scored on a 7-point scale (1 = absent, 2 = minimal, 3 = mild, 4 = moderate, 5 = moderately severe, 6 = severe, and 7 = extreme). The PANSS total score can range from 30 to 210. A higher score indicates worse symptoms. A negative change score indicates improvement.

Time frame:
Baseline to Week 48
Reported as:
Mean · Units on a scale
Change From Baseline to Week 48 in the PANSS Total Score
Units on a scaleCariprazine
Baseline66.5 ± 12.1
Change From Baseline-5.0 ± 14.0
SecondaryChange From Baseline to Week 48 in the CGI-S Score

The Clinical Global Impressions-Severity (CGI-S) scale is a 7-point scale that measures the overall severity of the illness compared with the severity of illness in other patients the Investigator has observed. The Investigator assesses the severity of the patient's illness as one of the following: 1 = Normal, not at all ill; 2 = Borderline ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill patients. The CGI-S score can range from 1 to 7. A higher score indicates more severe illness. A negative change score indicates improvement.

Time frame:
Baseline to Week 48
Reported as:
Mean · Units on a scale
Change From Baseline to Week 48 in the CGI-S Score
Units on a scaleCariprazine
Baseline3.0 ± 0.4
Change From Baseline-0.1 ± 0.8

Adverse events

Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cariprazine0/586 (0%)59/586 (10.1%)419/586 (71.5%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventCariprazine
SchizophreniaPsychiatric disorders25/586
Psychotic disorderPsychiatric disorders12/586
Social stay hospitalisationSocial circumstances6/586
Suicidal ideationPsychiatric disorders4/586
Vaginal haemorrhageReproductive system and breast disorders1/178
CellulitisInfections and infestations2/586
DepressionPsychiatric disorders2/586
Hallucination, auditoryPsychiatric disorders2/586
Schizophrenia, paranoid typePsychiatric disorders2/586
Autoimmune thrombocytopeniaBlood and lymphatic system disorders1/586
Most frequent other events
Showing 10 of 16
Most frequent other events
EventCariprazine
AkathisiaNervous system disorders118/586
HeadacheNervous system disorders104/586
InsomniaPsychiatric disorders104/586
Weight increasedInvestigations79/586
AnxietyPsychiatric disorders68/586
NauseaGastrointestinal disorders51/586
RestlessnessPsychiatric disorders49/586
Extrapyramidal disorderNervous system disorders47/586
TremorNervous system disorders46/586
DyspepsiaGastrointestinal disorders42/586

Baseline characteristics

The flexible-dose design for this study was selected to examine the relative safety and tolerability of a range of dosages of cariprazine. The starting dose of 1.5 mg/day was titrated as needed within the range of 3.0 - 9.0 mg/day based on the Investigator's judgment of response and tolerability.

Age, Continuous
Age, Continuous(years)Cariprazine
Mean39.1 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)Cariprazine
Female178
Male408
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cariprazine
Hispanic or Latino48
Not Hispanic or Latino523
Unknown or Not Reported15
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cariprazine
American Indian or Alaska Native1
Asian68
Native Hawaiian or Other Pacific Islander3
Black or African American229
White250
More than one race0
Unknown or Not Reported35
Weight
Weight(kg)Cariprazine
Mean79.94 ± 20.26
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Cariprazine
Mean27.10 ± 5.80
Waist circumference
Waist circumference(cm)Cariprazine
Mean91.76 ± 15.85
08

Study locations

86 sites
  • Forest Investigative Site 072
    Little Rock, Arkansas 72201, United States
  • Forest Investigative Site 021
    Little Rock, Arkansas 72211, United States
  • Forest Investigative Site 086
    Little Rock, Arkansas 72211, United States
  • Forest Investigative Site 014
    Springdale, Arkansas 72764, United States
  • Forest Investigative Site 080
    Carson, California 90746, United States
  • Forest Investigative Site 079
    Cerritos, California 90703, United States
  • Forest Investigative Site 048
    Costa Mesa, California 92626, United States
  • Forest Investigative Site 070
    Costa Mesa, California 92626, United States
  • Forest Investigative Site 022
    Garden Grove, California 92845, United States
  • Forest Investigative Site 083
    Garden Grove, California 92845, United States
  • Forest Investigative Site 050
    Long Beach, California 90813, United States
  • Forest Investigative Site 006
    Oceanside, California 92056, United States
  • Forest Investigative Site 003
    Riverside, California 92506, United States
  • Forest Investigative Site 016
    San Diego, California 92123, United States
  • Forest Investigative Site 073
    Santa Ana, California 92701, United States
  • Forest Investigative Site 071
    New Britain, Connecticut 06050, United States
  • Forest Investigative Site 002
    Bradenton, Florida 34208, United States
  • Forest Investigative Site 041
    Kissimmee, Florida 34741, United States
  • Forest Investigative Site 082
    North Miami, Florida 33161, United States
  • Forest Investigative Site 055
    Atlanta, Georgia 30308, United States
  • Forest Investigative Site 087
    Atlanta, Georgia 30308, United States
  • Forest Investigative Site 012
    Honolulu, Hawaii 96813, United States
  • Forest Investigative Site 018
    Chicago, Illinois 60640, United States
  • Forest Investigative Site 008
    Hoffman Estates, Illinois 60169, United States
  • Forest Investigative Site 044
    Rockville, Maryland 20850, United States
  • Forest Investigative Site 007
    Flowood, Mississippi 39232, United States
  • Forest Investigative Site 017
    Creve Coeur, Missouri 63141, United States
  • Forest Investigative Site 076
    Saint Charles, Missouri 63301, United States
  • Forest Investigative Site 045
    Saint Louis, Missouri 63118, United States
  • Forest Investigative Site 052
    Las Vegas, Nevada 89102, United States
  • Forest Investigative Site 004
    Willingboro, New Jersey 08046, United States
  • Forest Investigative Site 040
    Cedarhurst, New York 11516, United States
  • Forest Investigative Site 019
    Willoughby, Ohio 44094, United States
  • Forest Investigative Site 077
    Philadelphia, Pennsylvania 19131, United States
  • Forest Investigative Site 047
    Philadelphia, Pennsylvania 19139, United States
  • Forest Investigative Site 074
    Austin, Texas 78756, United States
  • Forest Investigative Site 084
    DeSoto, Texas 75115, United States
  • Forest Investigative Site 043
    Irving, Texas 75062, United States
  • Forest Investigative Site 078
    Bellevue, Washington 98007, United States
  • Forest Investigative Site 601
    Bello, Antioquia 051053, Colombia
  • Forest Investigative Site 604
    Pereira, Risaralda 660003, Colombia
  • Forest Investigative Site 602
    Bogota, 110121, Colombia
  • Forest Investigative Site 605
    Bogota, 111166, Colombia
  • Forest Investigative Site 503
    Ahmedabad, 380006, India
  • Forest Investigative Site 519
    Ahmedabad, 380006, India
  • Forest Investigative Site 501
    Ahmedabad, 380013, India
  • Forest Investigative Site 500
    Aurangabad, 431005, India
  • Forest Investigative Site 507
    Kanpur, 208005, India
  • Forest Investigative Site 518
    Lucknow, 226006, India
  • Forest Investigative Site 517
    Mangalore, 575001, India
  • Forest Investigative Site 515
    Mangalore, 575018, India
  • Forest Investigative Site 510
    Mumbai, 400026, India
  • Forest Investigative Site 513
    Nashik, 422101, India
  • Forest Investigative Site 509
    Rajkot, 360002, India
  • Forest Investigative Site 506
    Varanasi, 201010, India
  • Forest Investigative Site 505
    Vijaywada, 520002, India
  • Forest Investigative Site 306
    Bucuresti, 41914, Romania
  • Forest Investigative Site 301
    Cluj-Napoca, 400012, Romania
  • Forest Investigative Site 300
    Craiova, 200620, Romania
  • Forest Investigative Site 311
    Craiova, 200745, Romania
  • Forest Investigative Site 303
    Targoviste, 130086, Romania
  • Forest Investigative Site 304
    Targu Mures, 540142, Romania
  • Forest Investigative Site 102
    Arkhangelsk, 163530, Russian Federation
  • Forest Investigative Site 103
    Chelyabinsk, 454087, Russian Federation
  • Forest Investigative Site 104
    Chita, 672090, Russian Federation
  • Forest Investigative Site 110
    Saratov, 410028, Russian Federation
  • Forest Investigative Site 108
    Saratov, 410060, Russian Federation
  • Forest Investigative Site 112
    St. Petersburg, 190121, Russian Federation
  • Forest Investigative Site 105
    St. Petersburg, 192019, Russian Federation
  • Forest Investigative Site 106
    St. Petersburg, 192019, Russian Federation
  • Forest Investigative Site 113
    St. Petersburg, 192019, Russian Federation
  • Forest Investigative Site 107
    St. Petersburg, 193167, Russian Federation
  • Forest Investigative Site 109
    St. Petersburg, 197341, Russian Federation
  • Forest Investigative Site 100
    Tomsk, 634014, Russian Federation
  • Forest Investigative Site 211
    Glevakha, Kyiv Region 08631, Ukraine
  • Forest Investigative Site 206
    Kherson, Stepanivka 73488, Ukraine
  • Forest Investigative Site 208
    Dnipropetrovsk, 49005, Ukraine
  • Forest Investigative Site 205
    Dnipropetrovsk, 49027, Ukraine
  • Forest Investigative Site 200
    Donetsk, 83008, Ukraine
  • Forest Investigative Site 204
    Kharkiv, 61068, Ukraine
  • Forest Investigative Site 203
    Kharkov, 61068, Ukraine
  • Forest Investigative Site 201
    Kyiv, 04080, Ukraine
  • Forest Investigative Site 202
    Lviv, 79021, Ukraine
  • Forest Investigative Site 209
    Poltava, 36006, Ukraine
  • Forest Investigative Site 210
    Simferopol, 95006, Ukraine
  • Forest Investigative Site 207
    Vinnytsya, 21005, Ukraine
09

References and documents

Publications

  • Laszlovszky I, Barabassy A, Nemeth G. Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety. Adv Ther. 2021 Jul;38(7):3652-3673. doi: 10.1007/s12325-021-01797-5. Epub 2021 Jun 6. PubMed 34091867 ↗
  • Barabassy A, Sebe B, Acsai K, Laszlovszky I, Szatmari B, Earley WR, Nemeth G. Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies. Neuropsychiatr Dis Treat. 2021 Apr 7;17:957-970. doi: 10.2147/NDT.S301225. eCollection 2021. Erratum In: Neuropsychiatr Dis Treat. 2021 May 17;17:1481. doi: 10.2147/NDT.S316858. PubMed 33854317 ↗
  • Nasrallah HA, Earley W, Cutler AJ, Wang Y, Lu K, Laszlovszky I, Nemeth G, Durgam S. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis. BMC Psychiatry. 2017 Aug 24;17(1):305. doi: 10.1186/s12888-017-1459-z. PubMed 28836957 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2010 to primary completion in Jan 2013, 32 months.

Results were first posted in Jul 2019, 6 years 5 months after primary completion. A results delay was requested in Mar 2014.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 32 months is close to that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2010
First posted
Apr 15, 2010
StartActual
May 31, 2010
Primary completionActual
Jan 31, 2013
CompletionActual
Jan 31, 2013
Results delay requested
Mar 28, 2014
Results first posted
Jul 26, 2019
Last update
Jul 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01104792
Collaborators
Gedeon Richter Ltd.
Responsible party
Sponsor
First posted
Apr 15, 2010
Start date
May 31, 2010
Primary completion
Jan 31, 2013
Completion
Jan 31, 2013
Results posted
Jul 26, 2019
Last update
Jul 26, 2019

Study contacts

Raffaele Migliore, MA
study director · Forest Laboratories

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion